Difference between revisions of "Programmed death-ligand 1"

Jump to navigation Jump to search
no edit summary
Line 5: Line 5:
==Prognosis==
==Prognosis==
*Good prognosis - in high-grade [[ovarian serous carcinoma]], associated with [[tumour-infiltrating lymphocytes]].<ref name=pmid26972336>{{Cite journal  | last1 = Webb | first1 = JR. | last2 = Milne | first2 = K. | last3 = Kroeger | first3 = DR. | last4 = Nelson | first4 = BH. | title = PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. | journal = Gynecol Oncol | volume = 141 | issue = 2 | pages = 293-302 | month = May | year = 2016 | doi = 10.1016/j.ygyno.2016.03.008 | PMID = 26972336 }}</ref>
*Good prognosis - in high-grade [[ovarian serous carcinoma]], associated with [[tumour-infiltrating lymphocytes]].<ref name=pmid26972336>{{Cite journal  | last1 = Webb | first1 = JR. | last2 = Milne | first2 = K. | last3 = Kroeger | first3 = DR. | last4 = Nelson | first4 = BH. | title = PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. | journal = Gynecol Oncol | volume = 141 | issue = 2 | pages = 293-302 | month = May | year = 2016 | doi = 10.1016/j.ygyno.2016.03.008 | PMID = 26972336 }}</ref>
==Drugs==
*Atezolizumab.<ref name=pmid26970723>{{Cite journal  | last1 = Fehrenbacher | first1 = L. | last2 = Spira | first2 = A. | last3 = Ballinger | first3 = M. | last4 = Kowanetz | first4 = M. | last5 = Vansteenkiste | first5 = J. | last6 = Mazieres | first6 = J. | last7 = Park | first7 = K. | last8 = Smith | first8 = D. | last9 = Artal-Cortes | first9 = A. | title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. | journal = Lancet | volume =  | issue =  | pages =  | month = Mar | year = 2016 | doi = 10.1016/S0140-6736(16)00587-0 | PMID = 26970723 }}</ref>
==Application of PD-L1 antibodies==
==Application of PD-L1 antibodies==
PD-L1 antibodies are being used to treat:<ref name=pmid26895815>{{Cite journal  | last1 = Gandini | first1 = S. | last2 = Massi | first2 = D. | last3 = Mandalà | first3 = M. | title = PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. | journal = Crit Rev Oncol Hematol | volume = 100 | issue =  | pages = 88-98 | month = Apr | year = 2016 | doi = 10.1016/j.critrevonc.2016.02.001 | PMID = 26895815 }}</ref>
PD-L1 antibodies are being used to treat:<ref name=pmid26895815>{{Cite journal  | last1 = Gandini | first1 = S. | last2 = Massi | first2 = D. | last3 = Mandalà | first3 = M. | title = PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. | journal = Crit Rev Oncol Hematol | volume = 100 | issue =  | pages = 88-98 | month = Apr | year = 2016 | doi = 10.1016/j.critrevonc.2016.02.001 | PMID = 26895815 }}</ref>
*[[Malignant melanoma]].
*[[Malignant melanoma]].
*[[Non-small cell lung cancer]].
*[[Non-small cell lung cancer]].
**Associated with response predicted by [[tumour-infiltrating lymphocytes]] and ''PD-L1 IHC'' positivity of the tumour cells.<ref name=pmid26970723/>
*[[Renal cell carcinoma]].
*[[Renal cell carcinoma]].


48,536

edits

Navigation menu